ArticlesEarly chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial
Introduction
By the end of 1997, the United Nations' AIDS programme and the WHO estimated that 20·8 million adults were infected with HIV in sub-Saharan Africa.1 In Abidjan, Côte d'Ivoire, AIDS is the leading cause of adult death.2 In this large urban centre of West Africa, the prevalence of HIV infection has been estimated at 20% in adults attending outpatient services of community health centres,3 and more than 50% in many hospital departments.4 In Abidjan, where both HIV-1 and HIV-2 are present, more than 90% of HIV-infected people are infected with HIV-1, with or without HIV-2 coinfection.4 Public-health measures aim to improve the quality of life of HIV-1-infected patients, and to decrease the number of patients presenting with opportunistic infections.
Prevention of opportunistic infections could provide both individual and public-health benefits. However, international guidelines on HIV are difficult to tailor to the African environment, because of: the limited resources of HIV-1-infected people and health-care infrastructures; the different range of disease associated with HIV-1, including the overwhelming burden of tuberculosis as the primary cause of mortality and the low prevalence of Pneumocystis carinii infection;5, 6, 7 and the difficulty in basing chemoprophylaxis recommendations on a threshold of CD4-cell count when cell counting is not routinely available.8
Various bacterial and parasitic pathogens (other than Pneumocystis carinii) such as salmonella other than Salmonella typhi, Streptococcus pneumoniae, Toxoplasma gondii, and Isospora belli, are major nontuberculous causes of HIV-1-related morbidity in Africa.5, 9, 10, 11, 12 Trimethoprim-sulphamethoxazole (co-trimoxazole) prevents toxoplasmosis13 and isosporiasis,14 and might protect against HIV-1-related bacterial diseases,15, 16, 17, 18 which have a higher incidence in Africa than in industrialised countries,6 and occur at an earlier stage of HIV-1 immunosuppression than pneumocystis or toxoplasma infections.16, 19
We assessed the efficacy of co-trimoxazole prophylaxis in decreasing the occurrence of severe clinical events in African adults seropositive for HIV-1 at early stages of HIV-1 infection.
Section snippets
Patients
Our study was a randomised, placebo-controlled clinical trial, based on patients attending five community clinics in Yopougon, a district area of Abidjan, Côte d'Ivoire. The study protocol was approved by the ethics committees of both the national ivoirian programme on AIDS and the Bordeaux University Hospital in France, and the institutional review board of the French Agency of Research on AIDS (ANRS).
Between April 23, 1996, and March 17, 1998, HIV-infected adults aged 18 years and over, were
Results
843 HIV-infected patients were screened at the trial centre, and 545 were enrolled in the trial and randomly assigned to treatment (figure 1). The remaining 298 patients were not eligible: 12 were positive for HIV-2 only; eight were pregnant or lactating; 119 did not return; 29 lived outside Abidjan; six had a history of intolerance to sulphonamide; one had renal failure; two had haemoglobin less than 7 g/dL; 31 were WHO stage 1; and 90 were WHO stage 4. Among the 90 stage 4 patients, the two
Discussion
We found that the rate of severe events leading to death or hospital admission in African adults at clinical stage 2 and 3 of the WHO staging system20 was 43% lower with co-trimoxazole than with placebo. The occurrence of death or hospital admission was chosen as a primary outcome because: co-trimoxazole is likely to prevent many infectious diseases, thus, its efficacy had to be assessed on broad criteria; and hospital admission and death reflect the burden of opportunistic infections on both
References (26)
- et al.
Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya
Lancet
(1990) - et al.
Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya
Lancet
(1996) - et al.
Co-trimoxazole for childhood febrile illness in malaria-endemic regions
Lancet
(1991) Efficacy of trimethoprim-sulphamethoxazole chemoprophylaxis to decrease morbidity and mortality in HIV-1-associated tuberculosis in Côte d'Ivoire: a randomised controlled trial
Lancet
(1999)The current global situation of the HIV/AIDS pandemic
Whly Epidemiol Rec
(1997)- et al.
AIDS: the leading cause of adult death in the West African city of Abidjan, Ivory Coast
Science
(1990) - et al.
Clinical and immunological stages of HIV-infected patients attending community clinics, Abidjan, Côte d'Ivoire
Int J STD AIDS
(1998) - et al.
The epidemic of HIV/AIDS in Abidjan, Côte d'Ivoire: a review of data collected by Projet RETRO-CI from 1987 to 1993
J Acquir Immune Defic Syndr Hum Retrovirol
(1995) - et al.
The mortality and pathology of HIV infection in a West African city
AIDS
(1993) Prophylaxis for HIV-associated infections in the developing world
J Antimicrob Chemother
(1993)
Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda: a fibreoptic bronchoscopic study of 111 cases of undetermined aetiology
Am J Respir Crit Care Med
Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world
Am J Trop Med Hyg
Chronic diarrhoea among adults in Kigali, Rwanda: association with bacterial enteropathogens, rectocolonic inflammation, and human immunodeficiency virus infection
Clin Infect Dis
Cited by (359)
Clinical Features and Management of HIV/AIDS in Adults
2023, Manson's Tropical Diseases, Fourth EditionMalaria, sickle cell disease, HIV, and co-trimoxazole prophylaxis: An observational study
2018, International Journal of Infectious Diseases
Other members listed at end of paper